GT GTBIF Green Thumb Industries Loading... : Investor Sentiment and Bull/Bear Views

The author argues that MSOs use synthetic swaps and that this dynamic hurts Green Thumb specifically. The implied mechanism is that synthetic exposure in multi-state operators distorts or pressures Green Thumb's equity. No catalyst, target or timeframe is provided.

The author states they have tripled their Green Thumb Industries (GTI) position since Trump announced Schedule 3 rescheduling, treating the current period as an accumulation opportunity. The causal mechanism is that the stock is being manipulated downward until the DEA officially announces the Schedule 3 rescheduling, at which point the manipulation should end and the shares re-rate. The concrete catalyst is the official DEA announcement of Schedule 3. The main risk implied is that the DEA announcement may not come or may be delayed, leaving the manipulation in place.

The author disputes the claim that low trading volume is what keeps GTII's share price down, arguing instead that the real drags are revenue growth and EBITDA margins. They concede the company would benefit from cannabis reform, but insist volume is not the reason for the current valuation. No specific price target or timeframe is given; the main risk is that reform-driven re-rating could lift the stock regardless of current fundamentals.

The author bought 2,000 shares of GTII yesterday, calling it 'kinda crazy' that the stock is still priced at 10 CAD with basically no volume. The causal mechanism is that once trading volume picks up, the shares should re-rate to $20+ in the near future. The main risk implied is the current lack of liquidity and volume, which could persist and delay the re-rating.

The author favors GTBIF as the least volatile cannabis name with the best fundamentals. They expect a big win if/when S3 scheduling happens and the company uplists afterward. The tax write-off from the CGC loss is framed as helping when GTBIF takes off.

Author rotates Trulieve gains into Green Thumb Industries, arguing GTI is the 'quiet' MSO with a real multi-state footprint and solid balance sheet versus hyper-focused Florida-centric Trulieve. The catalyst is institutional money getting the green light on cannabis, which the author thinks gives GTI the best chance of returning to all-time highs. Main stated risk is that GTI gets bought out before it really runs, aided by Ben's family connections in the alcohol industry.

Author has been selling Trulieve on the way up and flipping all proceeds into a main Green Thumb Industries position while GTI lagged. The plan is to keep adding GTI below 7.50, funded by Trulieve premium, implying GTI is undervalued relative to TRLV. No explicit risk is stated beyond the rotation timing.

The author views Green Thumb as the beneficiary of a relative-value switch, arguing the price gap versus Trulieve is too wide for the fundamentals. The implied thesis is that Green Thumb is undervalued relative to Trulieve and should close the gap. No catalyst or timeframe is specified.

The author recommends adding GTI because it will win regardless of how the hemp ban goes, implying regulatory resilience. RYM is dismissed as a total gamble. No timeframe or risk is specified.

Author claims Green Thumb Industries is rapidly expanding THC drink retail distribution, with Rythm Drinks doubling store counts and entering new markets like Georgia and Illinois, and Circle K selling drinks in more states. This expansion should boost revenue and drive the stock higher if THC drinks are not banned; the next earnings report is a likely near-term catalyst. Main stated risk is regulatory action that could 'nuke' THC drinks.

Hedgeye Cannabis analyst issues a BUY signal on GTBIF at the open; McCullough amplifies the call, implying directional endorsement of the bullish thesis on the cannabis name.